The Cooper Companies vs Blue Sail Medical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

The Cooper Companies, Inc (COO)

Q3 20269 Sep – 18 Sep 2026

▲2▼1

Guidance cut and strategic review ends with CooperSurgical retained Cooper cut its fiscal 2026 revenue and profit outlook below what analysts expected and decided to keep its women's health unit, CooperSurgical, instead of selling it. The weak forecast and no-sale decision sent the stock down sharply, because investors had hoped a sale would unlock value.
This is the main new event that drove the stock down this period.
Buyback expanded to $3 billion Alongside the weak guidance, Cooper increased its share buyback program from $2 billion to $3 billion, leaving about $1.5 billion available. Buying back more stock can support the share price by reducing the number of shares outstanding, but it did not offset the negative reaction to the guidance cut.
This is a new capital action that partially offsets the negative guidance news.
Activist Jana Partners pushes for sale and CEO change Activist investor Jana Partners sent a letter urging Cooper to pursue a sale, replace its CEO, and consider selling assets. The stock rose 1.7% after hours on the news, as investors saw a chance for a shake-up that could boost value after a 34% year-to-date decline.
This is the latest new development that could change the company's direction and stock price.

September 20269 Sep – 18 Sep 2026

▲2▼1

Guidance cut and strategic review ends with CooperSurgical retained Cooper cut its fiscal 2026 revenue and profit outlook below what analysts expected and decided to keep its women's health unit, CooperSurgical, instead of selling it. The weak forecast and no-sale decision sent the stock down sharply, because investors had hoped a sale would unlock value.
This is the main new event that drove the stock down this period.
Buyback expanded to $3 billion Alongside the weak guidance, Cooper increased its share buyback program from $2 billion to $3 billion, leaving about $1.5 billion available. Buying back more stock can support the share price by reducing the number of shares outstanding, but it did not offset the negative reaction to the guidance cut.
This is a new capital action that partially offsets the negative guidance news.
Activist Jana Partners pushes for sale and CEO change Activist investor Jana Partners sent a letter urging Cooper to pursue a sale, replace its CEO, and consider selling assets. The stock rose 1.7% after hours on the news, as investors saw a chance for a shake-up that could boost value after a 34% year-to-date decline.
This is the latest new development that could change the company's direction and stock price.

Latest9 Sep – 18 Sep 2026

▲2▼1

Guidance cut and strategic review ends with CooperSurgical retained Cooper cut its fiscal 2026 revenue and profit outlook below what analysts expected and decided to keep its women's health unit, CooperSurgical, instead of selling it. The weak forecast and no-sale decision sent the stock down sharply, because investors had hoped a sale would unlock value.
This is the main new event that drove the stock down this period.
Buyback expanded to $3 billion Alongside the weak guidance, Cooper increased its share buyback program from $2 billion to $3 billion, leaving about $1.5 billion available. Buying back more stock can support the share price by reducing the number of shares outstanding, but it did not offset the negative reaction to the guidance cut.
This is a new capital action that partially offsets the negative guidance news.
Activist Jana Partners pushes for sale and CEO change Activist investor Jana Partners sent a letter urging Cooper to pursue a sale, replace its CEO, and consider selling assets. The stock rose 1.7% after hours on the news, as investors saw a chance for a shake-up that could boost value after a 34% year-to-date decline.
This is the latest new development that could change the company's direction and stock price.